Gara Jalqabaatti › Kansa Endometiriyaalii › Distaarikii Koloombiyaa › Washington
Qorannoo klinikaalii Kansa Endometiriyaalii Washington, DC keessatti
Qorannoo 18 Kansa Endometiriyaalii f Washington fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 3
- MedStar Washington Hospital Center, Washington D.C.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Namoota walitti qabaa jiraSadarkaa 2
- Walter Reed National Military Medical Center, Bethesda · Miili 7 fagaatti
- National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Namoota walitti qabaa jiraSadarkaa 2
- National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Georgetown University Medical Center, Washington D.C.
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Namoota walitti qabaa jiraSadarkaa 3
- MedStar Washington Hospital Center, Washington D.C.
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Namoota walitti qabaa jiraSadarkaa 3
- MedStar Washington Hospital Center ( Site 5005), Washington D.C.
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 3
- MedStar Washington Hospital, Washington D.C.
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Silver Spring · Miili 7 fagaatti
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Georgetown University Medical Center, Washington D.C.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Children's National Medical Center, Washington D.C.
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Normunity Investigational Site, Washington D.C.
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Johns Hopkins University, Sibley Memorial Hospital, Washington D.C.
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- National Institutes of Health, Bethesda · Miili 7 fagaatti
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Washington D.C.
- Research Site, Silver Spring · Miili 7 fagaatti
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Silver Spring · Miili 7 fagaatti
- Massive Bio SYNERGY-AI site, Bethesda · Miili 7 fagaatti
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Holy Cross Hospital, Silver Spring · Miili 7 fagaatti
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 2/3
- Maryland Oncology Hematology, P.A., Silver Spring · Miili 7 fagaatti
Qorannoo Kansa Endometiriyaalii magaalota biroo keessatti
- Houston, TXQorannoo 68
- New York City, NYQorannoo 52
- Boston, MAQorannoo 50
- Arlington, VAQorannoo 39
- Nashville, TNQorannoo 38
- Los Angeles, CAQorannoo 34
- St. Louis, MOQorannoo 29
- Philadelphia, PAQorannoo 28
- San Antonio, TXQorannoo 27
- Columbus, OHQorannoo 25
- Oklahoma City, OKQorannoo 25
- Chicago, ILQorannoo 25
Qorannoo biroo Washington keessatti
- Saree (Gosoota Hunda)Qorannoo 58
- Kansara Qara'a Non-Small CellQorannoo 55
- Saree OljooQorannoo 46
- Kansara MetastatikiiQorannoo 43
- Dhibee QaraQorannoo 41
- Kansarii ProstateQorannoo 38
- ObesityQorannoo 33
- Kansarii ColorectalQorannoo 29
- Dhibee Onneessaa fi DhiigaQorannoo 28
- Dukkana BladderQorannoo 26
- Leukemia Myeloidii HamaaQorannoo 24
- Kansarii OvariiQorannoo 23
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.